Conferences - Results from #80

Viewing 81-100 of 11487 articles

ASCO 2024: Avelumab + Axitinib vs Sunitinib in Patients with Advanced Renal Cell Carcinoma: Final Overall Survival Analysis from the JAVELIN Renal 101 Phase 3 Trial

ASCO 2024: Circulating Kidney Injury Molecule-1 Biomarker Analysis in IMmotion010: A Randomized Phase 3 Study of Adjuvant Atezolizumab vs Placebo in Patients with Renal Cell Carcinoma at Increased Risk of Recurrence After Resection

ASCO 2024: In It for the Long Run: Updated Outcomes From Phase III Trials

ASCO 2024: Impact of Exposure on Outcomes with Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer

ASCO 2024: S1600: Effects of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes: Primary Results from the Randomized Phase III Double-Blind Clinical Trial

ASCO 2024: PROs from a Randomized, Phase 3 Trial of Enfortumab Vedotin plus Pembrolizumab Versus Platinum-Based Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

ASCO 2024: PLATIPARP: A Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in Treatment of Patients with mCRPC with Homologous Recombination DNA Repair Deficiency

ASCO 2024: CLARIFY: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Patients with High-Risk Prostate Cancer Prior to Radical Prostatectomy (A Phase 3 Diagnostic Study)

ASCO 2024: ALADDIN: Evaluation of Darolutamide Addition to ADT and Radiation Therapy in Newly Diagnosed Prostate Cancer with Pelvic Lymph Nodes Metastases

ASCO 2024: FLEX-MRT: A Randomized Phase 2 Trial in Progress of Flexible and Extended Dosing of 177Lu-PSMA-617 Molecular Radioligand Therapy in mCRPC

ASCO 2024: ARASTEP: Darolutamide plus ADT in Patients with High-Risk Biochemical Recurrence of Prostate Cancer: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

ASCO 2024: Comparison of Outcomes with Docetaxel or ARPI Combination Therapy for mHSPC by Volume of Disease

ASCO 2024: Intensification of ADT with Enzalutamide in High-Risk Patients with Biochemical Relapse Following Radical Prostatectomy Undergoing Salvage Radiation: Initial Results from RTOG 3506 (STEEL)

ASCO 2024: A Phase 1/2 Study of ONCT-534-101, a Dual-Action Androgen Receptor Inhibitor, in Patients with mCRPC

ASCO 2024: Correlation of BMI with Survival Outcomes in Patients with mHSPC: Analysis of Patient-Level Data from SWOG 1216 Study

ASCO 2024: IMPLEMENT: Physicians Use of First-Line Treatment Intensification in mCSPC: A Discrete Choice Experiment

ASCO 2024: Cost Effectiveness Analysis of Nadofaragene Firadenovec for the Treatment of High-Risk, BCG–unresponsive, NMIBC from a US Third-Party Payer Perspective

ASCO 2024: Real-World Baseline Treatment Patterns and Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Olaparib in the United States

ASCO 2024: SECuRE: A Dose Escalation/Expansion Study to Assess the Anti-Tumor Efficacy of 67Cu-SAR-bisPSMA in Patients with Metastatic Castrate Resistant Prostate Cancer

ASCO 2024: Real-World Comparative Effectiveness and Cardiovascular Safety of Enzalutamide Versus Abiraterone Amongst Older Men Diagnosed with Metastatic Castration-Resistant Prostate Cancer

1
2
3
4
5
6
7
8
9
10